NCT03025958View on ClinicalTrials.gov

Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 13, 2017

Primary Completion Date

November 12, 2018

Study Completion Date

December 30, 2023

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Nimotuzumab

Concomitant nimotuzumab was given weekly at a dose of 200 mg from one week before the start of IMRT.

RADIATION

Radiation

Briefly, the dose prescribed was 70.4 Gy, 70.4 Gy, 60.8 Gy, and 54.4 Gy in 32 fractions delivered over 6 weeks at the periphery of the planning target volume (PTV)nx+rn, PTVnd, PTV1, and PTV2, respectively, using the simultaneous integrated boost technique.

Trial Locations (1)

310022

Xiaozhong Chen, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER

NCT03025958 - Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter